F0002-ADC

· Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for F0002-ADC, covering 2024-05-14 to 2024-05-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies. [Phase 1]